|
**Overview**: Obstetric Flow Panel**Introduction**: The Obstetric Flow Panel is a diagnostic tool designed to monitor obstetric immune status using whole blood samples. In India, recurrent pregnancy loss and preeclampsia affect ~1-5 percent of pregnancies, with immune dysregulation (abnormal CD4/CD8 ratio, low NK cells) implicated in some cases. High morbidity from under-monitoring in rural/low-SES pregnant women with bad obstetric history, limited flow labs, delayed IVIG or low-dose aspirin leading to miscarriage or fetal growth restriction. Per obstetrics practices aligned with ICMR, FOGSI, and Indian Society for Assisted Reproduction guidelines, the test employs flow cytometry for CD3, CD4, CD8, CD19, NK cells, total lymphocytes, and CD4/CD8 ratio over 1-2 days with high accuracy, valuable for assessing immune tolerance in recurrent miscarriage or preeclampsia risk. This diagnostic falls under immune profiling and targets women with recurrent loss or high-risk pregnancy, addressing accurate detection to guide immunomodulation or supportive care. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise obstetric immune assessment and reducing adverse outcomes. Its whole blood-based approach ensures reliable lymphocyte subset analysis.**Other Names**: Obstetric Flow Pnl.**FDA Status**: FDA approved, CLIA certified for hematology/immunology, compliant with 2025 standards.**Historical Milestone**: Lymphocyte subset panel in obstetrics standard; in India, used in high-risk pregnancy clinics.**Purpose**: The test assesses 7 parameters including CD3 to guide obstetric immune monitoring, assess lymphocyte subsets, inform therapy.**Test Parameters**: 1. CD3, 2. CD4, 3. CD8, 4. CD19, 5. NK Cells, 6. Total Lymphocytes, 7. CD4/CD8 Ratio.**Pretest Condition**: No fasting required; patients should have obstetric complications.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for flow).**Medical History**: Patients should provide details on miscarriage history, preeclampsia.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of immune dysregulation including loss, benefits of monitoring, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using flow cytometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low cell count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal subsets indicate immune imbalance, necessitating specialist input.**Specialist Consultation**: Fetal medicine specialists or immunologists should be consulted for management.**Additional Supporting Tests**: NK cytotoxicity, Th1/Th2 cytokines for confirmation.**Test Limitations**: Requires viable cells; comprehensive approach required.**References**: Indian Journal of Obstetrics and Gynaecology 2024, Obstetric Studies India 2023. |
